Results 11 to 20 of about 191 (111)
Huangkui capsule mitigates diabetic nephropathy via epigenetic therapy effects. [PDF]
Front PharmacolBackground Huangkui capsule (HKC), a Chinese herbal medicine derived from Abelmoschus manihot (L.) ethanol extract, has clinical efficacy against diabetic nephropathy (DN).
Yu Y, Tang H, Li N, Ge H, Wu J, Gu HF.
europepmc +2 more sources
Chemical constituents, clinical efficacy and molecular mechanisms of the ethanol extract of Abelmoschus manihot flowers in treatment of kidney diseases. [PDF]
Phytother Res, 2021 Abelmoschus manihot, also called as “Huangkui” in Chinese, is an annual flowering herb plant in the family of Malvaceae. As a traditional Chinese medicine, the ethanol extract of the flower in Abelmoschus manihot is made as Huangkui capsule and has been used for medication of the patients with kidney diseases.
Li N +8 more
europepmc +2 more sources
Evidence-Based Complementary and Alternative Medicine, 2023 Evidence-Based Complementary and Alternative Medicine, Volume 2023, Issue 1, 2023.
Evidence-Based Complementary and Alternative Medicine
openaire +2 more sources
Inhibition of Akt/mTOR/p70S6K Signaling Activity With Huangkui Capsule Alleviates the Early Glomerular Pathological Changes in Diabetic Nephropathy [PDF]
Frontiers in Pharmacology, 2018 Huangkui capsule (HKC), a Chinese modern patent medicine extracted from Abelmoschus manihot (L.) medic, has been widely applied to clinical therapy in the early diabetic nephropathy (DN) patients. However, it remains elusive whether HKC can ameliorate the inchoate glomerular injuries in hyperglycemia.
Qi-Jun Fang, Zi-Yue Wan, Tu Yue
exaly +4 more sources
Huangkui capsule combined with finerenone attenuates diabetic nephropathy by regulating the JAK2/STAT3 signaling pathway based on network pharmacology, molecular docking, and experimental verification. [PDF]
Front PharmacolIntroductionDiabetic nephropathy (DN) is a serious complication of diabetes with limited therapeutic options. Although Huangkui capsule (HKC) and finerenone individually show potential in DN management, their combined mechanism remains unclear.
Liu X +6 more
europepmc +4 more sources
Phytomedicine, 2019 Huangkui capsule (HKC), an anti-inflammatory Chinese modern patent medicine, has been now widely applied to the clinical therapy of diabetic nephropathy (DN). However, the overall therapeutic mechanisms in vivo are still unclear. Renal tubular epithelial-to-mesenchymal transition (EMT) is one of the major pathogenesis of renal interstitial fibrosis in ...
Yue Tu
exaly +3 more sources
Effects of the Huangkui capsule on chronic kidney disease: a systematic review and Meta-analysis. [PDF]
J Tradit Chin Med, 2023 Wei LI +7 more
europepmc +3 more sources
Linchuang shenzangbing zazhi, 2018 Objective To study the effect of Huangkui capsule inhibiting oxidative stress and fibrosis index in patients with diabetic kidney disease(DKD)with stageⅢ-Ⅳ,so as to explore the mechanism of Huangkui capsule in the treatment of DKD.Methods 100 patients ...
XU Ji-yao, ZHANG Yu, ZENG Qiao
doaj +1 more source
Efficacy and safety of Huangkui capsule for diabetic nephropathy
Medicine, 2021 Abstract Background: Diabetic nephropathy (DN) is 1 of the most serious complications of diabetes mellitus and the leading cause of end-stage renal disease in the world. Huangkui capsule, extracted from Abelmoschus manihot (L.) medic (AM), has been widely used to treat DN.
Wenrong An +5 more
openaire +2 more sources
Microbial Biotechnology, Volume 16, Issue 4, Page 813-826, April 2023., 2023 The plasma metabolites, mainly including amino acids and fatty acids such as methionine sulfoxide, BCAAs and cis‐7‐Hexadecenoic acid, exhibited a distinct return to normal after HKC treatment. The flora in the duodenum of NOD mice were more sensitive to HKC intervention, while that in the colon have more effect on the metabolism.
Ruiya Shi +7 more
wiley +1 more source